nuclear factor of activated T cells 5Genealiases: NF-AT5 · NFATL1 · NFATZ · OREBP · TONEBP
Q-omics provides the consensus-scored NFAT5 profile across patient tissues and cancer cell-line models. NFAT5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NFAT5 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NFAT5 RNA expression shows 21,159 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where NFAT5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFAT5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFAT5 survival associations across molecular data types. NFAT5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFAT5 RNA expression–survival associations across cancer types. High NFAT5 expression shows unfavorable associations in PAAD, CESC and LGG, but favorable associations in KIRC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for NFAT5 RNA expression.
This table summarizes NFAT5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NFAT5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFAT5 shows lower tumor expression in KIRC, BRCA, THCA and LUSC and higher tumor expression in HNSC and COAD. The KIRC box plot shows higher NFAT5 RNA expression in normal versus tumor tissue (log2 FC = −0.961, t-test p < 0.001).
This table shows molecular features associated with NFAT5 in patient tissues and cancer cell lines. In patient samples, NFAT5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NFAT5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
